Sight Sciences (SGHT) Income from Continuing Operations (2020 - 2026)
Sight Sciences (SGHT) posted quarterly Income from Continuing Operations of 12980000.0 for Q1 2026, up 8.29% year-over-year from 11985837.68 in Q1 2025, and down 211.87% quarter-over-quarter from 4162000.0 in Q4 2025.
Sight Sciences (SGHT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Sight Sciences' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 12980000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 8.29% year-over-year to 12980000.0; the TTM figure through Mar 2026 stood at 37252000.0 (up 24.58% YoY), while the FY2025 annual figure was 38426000.0, up 25.4% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 12980000.0, down from 4162000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4162000.0 in Q4 2025, with the low at 23843000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 13035000.0 (2023), against an average of 14394235.29.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 90.06% in 2022, then soared 64.87% in 2025.
- Sight Sciences' Income from Continuing Operations stood at 16907000.0 in 2022, then surged by 36.77% to 10691000.0 in 2023, then declined by 10.8% to 11846000.0 in 2024, then jumped by 64.87% to 4162000.0 in 2025, then slumped by 211.87% to 12980000.0 in 2026.
- Business Quant data shows SGHT's Income from Continuing Operations at 12980000.0 in Q1 2026, 4162000.0 in Q4 2025, and 8169000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Sight Sciences | 449.13 Mn | 369.37 Mn | 21.37 Mn | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.45 Mn |
| Mar 31, 2026 | -12.98 Mn |
| Dec 31, 2025 | -4.16 Mn |
| Sep 30, 2025 | -8.17 Mn |
| Jun 30, 2025 | -11.94 Mn |
| Mar 31, 2025 | -14.15 Mn |
| Dec 31, 2024 | -11.85 Mn |
| Sep 30, 2024 | -11.07 Mn |
| Jun 30, 2024 | -12.33 Mn |
| Mar 31, 2024 | -16.27 Mn |
| Dec 31, 2023 | -10.69 Mn |
| Sep 30, 2023 | -13.04 Mn |
| Jun 30, 2023 | -14.75 Mn |
| Mar 31, 2023 | -17.07 Mn |
| Dec 31, 2022 | -16.91 Mn |
| Sep 30, 2022 | -22.23 Mn |
| Jun 30, 2022 | -23.84 Mn |
| Mar 31, 2022 | -23.26 Mn |
| Dec 31, 2021 | -15.94 Mn |
| Sep 30, 2021 | -17.17 Mn |